#JIN-A02
LightNews LightNews
newsen.bsky.social
J INTS BIO Unveils Promising Results for JIN-A02, a Fourth-Generation EGFR Inhibitor#South_Korea#Seoul#J_INTS_BIO#EGFR_Inhibitor#JIN-A02
J INTS BIO Unveils Promising Results for JIN-A02, a Fourth-Generation EGFR Inhibitor
J INTS BIO has revealed groundbreaking clinical research on JIN-A02, a fourth-generation EGFR inhibitor, offering new hope for patients with lung cancer.
third-news.com
February 12, 2026 at 7:06 AM
rridrobot.bsky.social
The authors included RRIDs in their in Clinical Cancer Research paper! RRIDs improve reproducibility in scientific research. #accelerateopenscience #STMpublishing #reproducibility
JIN-A02, a Mutant-Selective Fourth-Generation EGFR inhibitor, Overcomes C797S-Mediated Resistance and Demonstrates Intracranial Activity in NSCLC
Read the full paper: JIN-A02, a Mutant-Selective Fourth-Generation EGFR inhibitor, Overcomes C797S-Mediated Resistance and Demonstrates Intracranial Activity in NSCLC
doi.org
May 6, 2026 at 7:01 AM
sptimes.bsky.social
J INTS BIO Presents Research Results for Next-Generation Innovative Anticancer Therapeutics 'JIN-A02' and 'JIN-001' at AACR 2025
SEOUL, South Korea, April 30, 2025 /PRNewswire/ -- J INTS BIO, a company specializing in anticancer and orphan drugs, announced its research findings for the next-generation EGFR-TKI therapeutic 'JIN-A02' (clinical Phase 1/2 results) and the ovarian cancer treatment candidate 'JIN-001' (preclinical ...
dlvr.it
April 30, 2025 at 6:15 AM
laotiantimes.com.web.brid.gy
J INTS BIO Reports Fourth-Generation EGFR Inhibitor JIN-A02 in Clinical Cancer Research
SEOUL, South Korea, Feb. 12, 2026 /PRNewswire/ — J INTS BIO, Inc. announced that research findings on its investigational fourth-generation EGFR tyrosine kinase inhibitor (TKI), JIN-A02, have been published in Clinical Cancer Research, a leading oncology journal published by the American Association for Cancer Research (AACR). According to the most recent Journal Citation Reports (2025), […]
laotiantimes.com
February 12, 2026 at 8:12 AM
newsen.bsky.social
J INTS BIO Unveils Promising Clinical Results of JIN-A02 at ASCO 2025#South_Korea#Seoul#J_INTS_BIO#JIN-A02#EGFR-TKI
J INTS BIO Unveils Promising Clinical Results of JIN-A02 at ASCO 2025
J INTS BIO has shared interim findings from its clinical trial for JIN-A02, a fourth-generation EGFR-TKI, showing notable anti-tumor activity.
third-news.com
June 2, 2025 at 2:29 AM
l2plabs.bsky.social
J INTS BIO Reports Fourth-Generation EGFR Inhibitor JIN-A02 in Clinical Cancer Research
SEOUL, South Korea, Feb. 12, 2026 /PRNewswire/ -- J INTS BIO, Inc. announced that research findings on its investigational fourth-generation EGFR tyrosine kinase inhibitor (TKI), JIN-A02, have been published in Clinical Cancer Research, a leading oncology journal published by the American...
dlvr.it
February 12, 2026 at 7:06 AM
l2plabs.bsky.social
J INTS BIO to Present Global Clinical Results from JIN-A02, a Fourth-Generation EGFR-TKI, at ASCO 2025
Significant anti-tumor responses and reduction of brain metastases observed SEOUL, South Korea , June 1, 2025 /PRNewswire/ -- J INTS BIO, a company specializing in the development of therapeutics for cancer and rare diseases, officially announced interim results from the global Phase 1/2...
dlvr.it
June 2, 2025 at 2:53 AM
l2plabs.bsky.social
J INTS BIO Presents Research Results for Next-Generation Innovative Anticancer Therapeutics 'JIN-A02' and 'JIN-001' at AACR 2025
SEOUL, South Korea, April 30, 2025 /PRNewswire/ -- J INTS BIO, a company specializing in anticancer and orphan drugs, announced its research findings for the next-generation EGFR-TKI therapeutic 'JIN-A02' (clinical Phase 1/2 results) and the ovarian cancer treatment candidate 'JIN-001'...
dlvr.it
April 30, 2025 at 5:16 AM
drtimos.bsky.social
Thoughts on this? >> J INTS BIO to Present Global Clinical Results from JIN-A02,
a Fourth-Generation EGFR-TKI, at ASCO 2025 >> Comment below! #AI #healthtech #IoT #industry40 #mhealth
J INTS BIO to Present Global Clinical Results from JIN-A02, a Fourth-Generation EGFR-TKI, at ASCO 2025
Significant anti-tumor responses and reduction of brain metastases observed SEOUL, South Korea  , June 1, 2025 /PRNewswire/ — J INTS BIO, a company specializing in the development of therapeutics for cancer and rare diseases, officially announced interim results from the global Phase 1/2 clinical trial of JIN-A02, its fourth-generation EGFR-TKI drug candidate, at the American Society …
dlvr.it
June 2, 2025 at 2:45 AM